{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:31:38Z","timestamp":1792794698184,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-014"],"award-info":[{"award-number":["2022-PUMCH-B-014"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-006"],"award-info":[{"award-number":["2022-PUMCH-D-006"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2501700"],"award-info":[{"award-number":["2021YFC2501700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-002"],"award-info":[{"award-number":["2021-I2M-1-002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04430-5","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T14:45:29Z","timestamp":1758293129000},"page":"941-951","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of denosumab biosimilar CMAB807 versus Prolia\u00ae in Chinese postmenopausal women with osteoporosis"],"prefix":"10.1007","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4434-3462","authenticated-orcid":false,"given":"Yan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingwu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maozhong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lige","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aige","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6164-4611","authenticated-orcid":false,"given":"Yajun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-5536","authenticated-orcid":false,"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"issue":"3","key":"4430_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2106\/JBJS.I.00919","volume":"92","author":"A Unnanuntana","year":"2010","unstructured":"A. Unnanuntana, B.P. Gladnick, E. Donnelly et al., The assessment of fracture risk. J. Bone Joint Surg. Am. 92(3), 743\u2013753 (2010)","journal-title":"J. Bone Joint Surg. Am."},{"issue":"1","key":"4430_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"T S\u00f6zen","year":"2017","unstructured":"T. S\u00f6zen, L. \u00d6z\u0131\u015f\u0131k, N. Ba\u015faran, An overview and management of osteoporosis. Eur. J. Rheumatol. 4(1), 46\u201356 (2017)","journal-title":"Eur. J. Rheumatol."},{"key":"4430_CR3","doi-asserted-by":"publisher","first-page":"882241","DOI":"10.3389\/fendo.2022.882241","volume":"13","author":"YY Shen","year":"2019","unstructured":"Y.Y. Shen, X. Huang, J.Y. Wu et al., The global burden of osteoporosis, low bone mass, and its related fracture in 204 countries and territories, 1990\u20132019. Front. Endocrinol. 13, 882241 (2019)","journal-title":"Front. Endocrinol."},{"key":"4430_CR4","doi-asserted-by":"crossref","unstructured":"L.H. Wang, W. Yu, X.J. Yin et al., Prevalence of osteoporosis and fracture in china: the China osteoporosis prevalence study. JAMA Netw. Open. 4(8), e2121106 (2021)","DOI":"10.1001\/jamanetworkopen.2021.21106"},{"issue":"3","key":"4430_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMcp1513724","volume":"374","author":"DM Black","year":"2016","unstructured":"D.M. Black, C.J. Rosen, C.G. Solomon, Clinical practive. Postmenopausal osteoporosis. N Engl. J. Med. 374(3), 254\u2013262 (2016)","journal-title":"N Engl. J. Med."},{"issue":"1","key":"4430_CR6","doi-asserted-by":"publisher","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","volume":"2","author":"R Eastell","year":"2016","unstructured":"R. Eastell, T.W. O\u2019Neill, L.C. Hofbauer et al., Postmenopausal osteoporosis. Nat. Rev. Dis. Primers. 2(1), 16069 (2016)","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"9773","key":"4430_CR7","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","volume":"377","author":"TD Rachner","year":"2011","unstructured":"T.D. Rachner, S. khosla, L.C. Hofbauer et al., Osteoporosis: now and the future. Lancet. 377(9773), 1276\u20131287 (2011)","journal-title":"Lancet"},{"issue":"9156","key":"4430_CR8","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"J.R. Center, T.V. Nguyen, D. Schneider et al., Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 353(9156), 878\u2013882 (1999)","journal-title":"Lancet"},{"issue":"7","key":"4430_CR9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00198-015-3093-2","volume":"26","author":"L Si","year":"2015","unstructured":"L. Si, T.M. Winzenberg, Q. Jiang, M. Chen, A.J. Palmer, Projection of osteoporosis-related fractures and costs in china: 2010\u20132050. Osteoporos. Int. 26(7), 1929\u20131937 (2015)","journal-title":"Osteoporos. Int."},{"issue":"5","key":"4430_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"D.L. Lacey, W.J. Boyle, W.S. Simonet et al., Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 11(5), 401\u2013419 (2012)","journal-title":"Nat. Rev. Drug Discov"},{"issue":"8","key":"4430_CR11","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"S.R. Cummings, M.J. San, M.R. Mcclung et al., Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Eng. J. Med. 361(8), 756\u2013765 (2009)","journal-title":"N Eng. J. Med."},{"issue":"1","key":"4430_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"N. Freemantle, S. Satram-Hoang, E.T. Tang et al., Final results of the DAPS (Denosumab adherence preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos. Int. 23(1), 317\u2013326 (2012)","journal-title":"Osteoporos. Int."},{"key":"4430_CR13","doi-asserted-by":"publisher","first-page":"821944","DOI":"10.3389\/fphar.2022.821944","volume":"13","author":"HJ Chen","year":"2022","unstructured":"H.J. Chen, W. Chen, F. Yuan et al., Pharmacokinetics, pharmacodynamics, safety and immunogenicity of CMAB807, a new denosumab biosimilar, in healthy Chinese subjects. Front. Pharmacol. 13, 821944 (2022)","journal-title":"Front. Pharmacol."},{"issue":"1","key":"4430_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s43441-021-00342-4","volume":"56","author":"NE Storm","year":"2022","unstructured":"N.E. Storm, W. Chang, T.C. Lin et al., A novel case study of the use of Real-World evidence to support the registration of an osteoporosis product in China. Ther. Innov. Regul. Sci. 56(1), 137\u2013144 (2022)","journal-title":"Ther. Innov. Regul. Sci."},{"issue":"2","key":"4430_CR15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41401-022-00954-y","volume":"44","author":"H Zhang","year":"2023","unstructured":"H. Zhang, J.M. Gu, A.J. Chao et al., A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk. Acta Pharmacol. Sin. 44(2), 446\u2013453 (2023)","journal-title":"Acta Pharmacol. Sin"},{"key":"4430_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jot.2022.06.007","volume":"38","author":"JM Gu","year":"2022","unstructured":"J.M. Gu, H. Zhang, Q.Y. Xue et al., Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: a randomized, double-blind, placebo-controlled, multicenter phase III study. J. Orthop. Translat. 38, 117\u2013125 (2022)","journal-title":"J. Orthop. Translat"},{"issue":"7","key":"4430_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/14712598.2024.2352587","volume":"24","author":"Y Jiang","year":"2024","unstructured":"Y. Jiang, Y.N. Huo, Y.F. Li et al., Randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis. Expert Opin. Biol. Ther. 24(7), 665\u2013672 (2024)","journal-title":"Expert Opin. Biol. Ther."},{"key":"4430_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/ijp.IJP_346_19","volume":"53","author":"I Singh","year":"2021","unstructured":"I. Singh, V. Jose, R. Patel, S. Arora, Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial. Indian J. Pharmacol. 53, 6\u201312 (2021)","journal-title":"Indian J. Pharmacol."},{"issue":"1","key":"4430_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13075-022-02840-8","volume":"24","author":"A Jamshidi","year":"2022","unstructured":"A. Jamshidi, M. Vojdanian, M. Soroush et al., Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia\u00ae) in postmenopausal osteoporosis: a phase III, randomized, two\u2013armed, double\u2013blind, parallel, active\u2013controlled, and non-inferiority clinical trial. Arthritis Res. Ther. 24(1), 161 (2022)","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"4430_CR20","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00198-024-07161-x","volume":"35","author":"JY Reginster","year":"2024","unstructured":"J.Y. Reginster, E. Czerwinski, K. Wilk et al., Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, phase 3 trial in postmenopausal women with osteoporosis. Osteoporos. Int. 35(11), 1919\u20131930 (2024)","journal-title":"Osteoporos. Int."},{"key":"4430_CR21","doi-asserted-by":"crossref","unstructured":"L. Bente, C. Yoon-Sok, P. Rafal et al., Proposed denosumab biosimilar SB16 vs reference denosumab in postmenopausal osteoporosis: phase 3 results up to month 12. J. Clin. Endocrinol. Metab. 110(6), e1951-e1958 (2025)","DOI":"10.1210\/clinem\/dgae611"},{"issue":"7","key":"4430_CR22","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1359\/jbmr.2000.15.7.1398","volume":"15","author":"A Roger","year":"2000","unstructured":"A. Roger, R.A. Hannon, R. Eastell, Biochemical markers as predictors of rates of bone loss after menopause. J. Bone Min. Res. 15(7), 1398\u20131404 (2000)","journal-title":"J. Bone Min. Res."},{"issue":"2","key":"4430_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"S. Vasikaran, R. Eastell, O. Bruy\u00e8re et al., Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos. Int. 22(2), 391\u2013420 (2011)","journal-title":"Osteoporos. Int."},{"issue":"2","key":"4430_CR24","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00198-014-2964-2","volume":"26","author":"T Sugimoto","year":"2015","unstructured":"T. Sugimoto, T. Matsumoto, T. Hosoi et al., Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the denosumab fracture intervention randomized placebo controlled trial (DIRECT). Osteoporos. Int. 26(2), 765\u2013774 (2015)","journal-title":"Osteoporos. Int."},{"issue":"7","key":"4430_CR25","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"P.J. Bekker, D.L. Holloway, A.S. Rasmussen et al., A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Min. Res. 19(7), 1059\u20131066 (2004)","journal-title":"J. Bone Min. Res."},{"issue":"4","key":"4430_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/cen.12188","volume":"79","author":"P Makras","year":"2013","unstructured":"P. Makras, S.A. Polyzos, A. Papatheodorou et al., Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin. Endocrinol. (Oxf). 79(4), 499\u2013503 (2013)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"4430_CR27","doi-asserted-by":"crossref","unstructured":"H.F. Gu, L.J. Gu, Y. Wu et al., Efficacy and safety of denosumab in postmenopausal women with osteoporosis: A Meta-Analysis. Med. (Baltim). 94(44), e1674 (2015)","DOI":"10.1097\/MD.0000000000001674"},{"issue":"4","key":"4430_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/ajco.12517","volume":"13","author":"K Pittman","year":"2017","unstructured":"K. Pittman, Y.C. Antill, A. Goldrick et al., Denosumab: prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. Asia Pac. J. Clin. Oncol. 13(4), 266\u2013276 (2017)","journal-title":"Asia Pac. J. Clin. Oncol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04430-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04430-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04430-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:09:05Z","timestamp":1761736145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04430-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4430"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04430-5","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}